Trials / Conditions / Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

22 registered clinical trials studyying Generalized Pustular Psoriasis — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Generalized Pustular Psoriasis Registry in Costa Rica NCT07448428	Caja Costarricense de Seguro Social	—
Withdrawn	Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis NCT06886009	Boehringer Ingelheim	—
Recruiting	A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis NCT07314060	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
Recruiting	Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis NCT06477536	Shanghai Huaota Biopharmaceutical Co., Ltd.	Phase 2 / Phase 3
Active Not Recruiting	A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) NCT06433531	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Phase 1
Active Not Recruiting	A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis NCT06323356	Takeda	Phase 3
Active Not Recruiting	A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic NCT06295692	Janssen Pharmaceutical K.K.	Phase 3
Active Not Recruiting	A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment f NCT06013969	Boehringer Ingelheim	Phase 4
Recruiting	CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry NCT06100991	CorEvitas	—
Completed	PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms NCT05670821	Boehringer Ingelheim	—
Completed	HB0034 in Patients With Generalized Pustular Psoriasis (GPP) NCT05512598	Shanghai Huaota Biopharmaceutical Co., Ltd.	Phase 1
Terminated	Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With NCT05366855	Vanda Pharmaceuticals	Phase 3
Completed	Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP NCT05352893	Vanda Pharmaceuticals	Phase 3
Completed	An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Ps NCT05239039	Boehringer Ingelheim	Phase 3
Completed	An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psor NCT05200247	Boehringer Ingelheim	Phase 3
Completed	A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoria NCT04399837	Boehringer Ingelheim	Phase 2
Completed	A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythroderm NCT03942042	Eli Lilly and Company	Phase 4
Completed	Biologic Therapy for Generalized Pustular Psoriasis NCT06391996	Chao Ji	—
Active Not Recruiting	Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psorias NCT03886246	Boehringer Ingelheim	Phase 2
Completed	Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Gene NCT03782792	Boehringer Ingelheim	Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoria NCT03619902	Vanda Pharmaceuticals	Phase 2
Unknown	Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence NCT04566471	Peking University Third Hospital	—